Brian J Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6361606/publications.pdf

Version: 2024-02-01

126 6,052 38 papers citations h-index

126 126 126 6706
all docs docs citations times ranked citing authors

75

g-index

#	Article	IF	CITATIONS
1	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	4.9	544
2	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 2012, 11, 6-19.	0.5	399
3	Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline. Journal of Urology, 2013, 190, 441-449.	0.4	368
4	Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. International Journal of Radiation Oncology Biology Physics, 2004, 59, 419-425.	0.8	325
5	External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. International Journal of Radiation Oncology Biology Physics, 1997, 37, 753-759.	0.8	183
6	Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 3864-3871.	1.6	177
7	Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines. International Journal of Radiation Oncology Biology Physics, 2013, 86, 822-828.	0.8	161
8	A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy. PLoS ONE, 2008, 3, e2318.	2. 5	160
9	Planning Target Margin Calculations for Prostate Radiotherapy Based on Intrafraction and Interfraction Motion Using Four Localization Methods. International Journal of Radiation Oncology Biology Physics, 2008, 70, 289-295.	0.8	148
10	URINARY FISTULAS FOLLOWING EXTERNAL RADIATION OR PERMANENT BRACHYTHERAPY FOR THE TREATMENT OF PROSTATE CANCER. Journal of Urology, 2005, 173, 1953-1957.	0.4	145
11	Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology, 2018, 8, 28-39.	2.1	140
12	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
13	The radial distance of extraprostatic extension of prostate carcinoma., 1999, 85, 2630-2637.		134
14	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7〓10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 341-346.	0.8	126
15	LC-MS/MS Quantification of Zn-α2 Glycoprotein: A Potential Serum Biomarker for Prostate Cancer. Clinical Chemistry, 2007, 53, 673-678.	3.2	123
16	Metastatic prostate carcinoma to bone. Cancer, 2002, 95, 1028-1036.	4.1	122
17	Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Frontiers in Oncology, 2012, 2, 215.	2.8	107
18	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncology, The, 2016, 17, 1435-1444.	10.7	107

#	Article	IF	CITATIONS
19	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	3.8	106
20	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research, 2015, 75, 4688-4696.	0.9	105
21	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1472-1477.	0.8	92
22	Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1131-1140.	0.8	85
23	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.8	77
24	Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. Journal of Urology, 2006, 176, 2020-2024.	0.4	73
25	Prostate brachytherapy seed localization by analysis of multiple projections: Identifying and addressing the seed overlap problem. Medical Physics, 2004, 31, 1277-1287.	3.0	62
26	A Preclinical Large Animal Model of Adenovirus-Mediated Expression of the Sodium–lodide Symporter for Radioiodide Imaging and Therapy of Locally Recurrent Prostate Cancer. Molecular Therapy, 2005, 12, 835-841.	8.2	62
27	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1061-1065.	0.8	59
28	Natural History of Clinical Recurrence Patterns of Lymph Node–Positive Prostate Cancer After Radical Prostatectomy. European Urology, 2016, 69, 135-142.	1.9	58
29	PROSTATE BRACHYTHERAPY SEED MIGRATION TO THE RIGHT VENTRICLE FOUND AT AUTOPSY FOLLOWING ACUTE CARDIAC DYSRHYTHMIA. Journal of Urology, 2000, 164, 1661-1661.	0.4	57
30	Magnetic Resonance Imaging-guided Cryoablation of Recurrent Prostate Cancer After Radical Prostatectomy: Initial Single Institution Experience. Urology, 2013, 82, 870-875.	1.0	56
31	Prostate Brachytherapy Seed Migration To A Coronary Artery Found During Angiography. Journal of Urology, 2002, 168, 1103-1103.	0.4	51
32	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348.	1.9	51
33	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
34	Telemedicine in radiotherapy treatment planning: requirements and applications. Radiotherapy and Oncology, 2000, 54, 255-259.	0.6	48
35	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy, 2007, 6, 2-8.	0.5	47
36	Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology, 2000, 56, 726-729.	1.0	45

#	Article	IF	Citations
37	Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with ¹¹ C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2017, 197, 129-134.	0.4	45
38	Prostate Cryotherapy Monitoring Using Vibroacoustography: Preliminary Results of an <i>Ex Vivo</i> Study and Technical Feasibility. IEEE Transactions on Biomedical Engineering, 2008, 55, 2584-2592.	4.2	44
39	Electronic and film portal images: a comparison of landmark visibility and review accuracy. International Journal of Radiation Oncology Biology Physics, 2002, 54, 584-591.	0.8	42
40	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2018, 129, 377-386.	0.6	39
41	A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy, 2012, 11, 299-305.	0.5	35
42	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535.	0.8	35
43	Progress in Gene Therapy for Prostate Cancer. Frontiers in Oncology, 2012, 2, 172.	2.8	34
44	The radial distance of extraprostatic extension of prostate carcinoma. Cancer, 1999, 85, 2630-2637.	4.1	34
45	3D visualization, analysis, and treatment of the prostate using trans-urethral ultrasound. Computerized Medical Imaging and Graphics, 2003, 27, 339-349.	5.8	30
46	Low dose rate prostate brachytherapy. Translational Andrology and Urology, 2018, 7, 341-356.	1.4	30
47	ACR Appropriateness Criteria \hat{A}^{\otimes} external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Advances in Radiation Oncology, 2017, 2, 62-84.	1.2	30
48	Seed localization and TRUS-fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. Computer Aided Surgery, 2007, 12, 25-34.	1.8	29
49	Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry. Physics in Medicine and Biology, 2007, 52, 3105-3119.	3.0	28
50	Treatment of Prostate Cancer Local Recurrence After Radical Retropubic Prostatectomy with 17-Gauge Interstitial Transperineal Cryoablation: Initial Experience. Urology, 2007, 70, 80-85.	1.0	28
51	Examination of dosimetry accuracy as a function of seed detection rate in permanent prostate brachytherapy. Medical Physics, 2005, 32, 3049-3056.	3.0	27
52	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Practical Radiation Oncology, 2016, 6, e117-e126.	2.1	26
53	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy, 2017, 16, 266-276.	0.5	26
54	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.5	26

#	Article	IF	CITATIONS
55	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2014, 13, 27-31.	0.5	24
56	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 229-240.	0.8	24
57	Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 767-776.	0.8	23
58	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Advances in Radiation Oncology, 2017, 2, 437-454.	1.2	21
59	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6376-6383.	7.0	21
60	Measurement of the ultrasound backscatter signal from three seed types as a function of incidence angle: Application to permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1174-1182.	0.8	20
61	Long-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1938-1943.	0.8	20
62	Long-term outcomes of radiotherapy for stage II testicular seminoma–the Mayo Clinic experience. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1832-1838.	1.6	20
63	ACR Appropriateness Criteria ® Post-treatmentÂFollow-up Prostate Cancer. Journal of the American College of Radiology, 2018, 15, S132-S149.	1.8	20
64	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.6	20
65	Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression. Cancer Journal (Sudbury, Mass), 2004, 10, 343-348.	2.0	19
66	Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy, 2019, 18, 1-7.	0.5	19
67	A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1082-1089.	0.8	19
68	Prediction of Radial Distance of Extraprostatic Extension FromÂPretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.8	18
69	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871.	7.1	18
70	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
71	Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Current Opinion in Urology, 2003, 13, 117-122.	1.8	17
72	Brachytherapy in the Management of Prostate Cancer. Surgical Oncology Clinics of North America, 2017, 26, 491-513.	1.5	17

#	Article	IF	CITATIONS
73	Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil. Practical Radiation Oncology, 2017, 7, 42-49.	2.1	17
74	Application of vibro-acoustography in prostate tissue imaging. Medical Physics, 2013, 40, 022902.	3.0	14
75	Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy, 2003, 2, 98-102.	0.5	13
76	ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 278-288.	1.3	13
77	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using ¹¹ C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. Journal of Urology, 2018, 199, 726-733.	0.4	13
78	The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer, 2002, 95, 513-519.	4.1	12
79	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminomaâ€"The Mayo Clinic experience. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 24.e1-24.e6.	1.6	12
80	Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy, 2019, 18, 306-312.	0.5	12
81	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12
82	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146.	1.9	12
83	Estimated limits of IMRT dose escalation using varied planning target volume margins. Physics in Medicine and Biology, 2008, 53, 3777-3788.	3.0	11
84	The American Board of Radiology Initial Certification in Radiation Oncology: Moving Forward Through Collaboration. International Journal of Radiation Oncology Biology Physics, 2019, 104, 21-23.	0.8	11
85	Fluoroscopy to ultrasound image registration using implanted seeds as fiducials during permanent prostate brachytherapy. , 2004, , .		10
86	Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. Urology, 2006, 68, 810-814.	1.0	10
87	Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer and Prostatic Diseases, 2021, 24, 514-523.	3.9	10
88	Prostate brachytherapy seed reconstruction using an adaptive grouping technique. Medical Physics, 2007, 34, 2975-2984.	3.0	9
89	Late gastrointestinal morbidity in patients with stage l–ll testicular seminoma treated with radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 496-500.	1.6	9
90	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Advances in Radiation Oncology, 2019, 4, 314-322.	1.2	9

#	Article	IF	CITATIONS
91	¹¹ C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen 3% 0.1 ng/ml. Journal of Cancer Research and Therapeutics, 2021, 17, 358.	0.9	8
92	Prostate brachytherapy seed migration to a coronary artery found during angiography. Journal of Urology, 2002, 168, 1103.	0.4	8
93	Multimodality Therapy Including Surgical Resection and Intraoperative Electron Radiotherapy for Recurrent or Advanced Primary Carcinoma of the Urinary Bladder or Ureter. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 596-600.	1.3	7
94	Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence. Clinical Genitourinary Cancer, 2019, 17, e536-e540.	1.9	6
95	Comparing bowel and urinary domains of patientâ€reported quality of life at the end of and 3 months post radiotherapy between intensityâ€modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Medicine, 2020, 9, 7925-7934.	2.8	6
96	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
97	The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer. Radiotherapy and Oncology, 2021, 161, 9-15.	0.6	6
98	Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU International, 2006, 98, 773-776.	2.5	5
99	Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus '. Radiation Oncology, 2014, 9, 171.	2.7	5
100	Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. Journal of Contemporary Brachytherapy, 2016, 5, 371-378.	0.9	5
101	178 Supplemental implantation for suboptimal permanent prostate brachytherapy: A prostate phantom study. Radiotherapy and Oncology, 2000, 55, 91-92.	0.6	4
102	Brachytherapy Seed Localization from Fluoroscopic Images Using a Statistical Classifier. Lecture Notes in Computer Science, 2003, , 945-946.	1.3	4
103	Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm. Brachytherapy, 2004, 3, 106-112.	0.5	4
104	The Relationship of the Intensity of Posttreatment Prostate-Specific Antigen Surveillance and Prostate Cancer Outcomes: Results From a Population-Based Cohort. Mayo Clinic Proceedings, 2012, 87, 540-547.	3.0	4
105	Feasibility of vibroâ€acoustography with a quasiâ€2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: A pilot <i>ex vivo</i> study. Medical Physics, 2014, 41, 092902.	3.0	4
106	TRUS-fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. Studies in Health Technology and Informatics, 2006, 119, 532-7.	0.3	4
107	<title>Transurethral ultrasound of the prostrate for applications in prostrate brachytherapy: analysis of phantom and in-vivo data</title> ., 2001,,.		3
108	Vibro-acoustography with 1.75D ultrasound array transducer for detection and localization of permanent prostate brachytherapy seeds: ex vivostudy. , 2013, , .		3

#	Article	IF	CITATIONS
109	Shape analysis of the prostate: Establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance. Brachytherapy, 2014, 13, 465-470.	0.5	2
110	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Advances in Radiation Oncology, 2019, 4, 79-89.	1.2	2
111	Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT). Current Opinion in Urology, 2021, 31, 199-205.	1.8	2
112	Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. Practical Radiation Oncology, 2021, 11, e468-e476.	2.1	2
113	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder, 2018, 5, e34.	0.2	2
114	Morbidity After Brachytherapy for Prostate Adenocarcinoma. Mayo Clinic Proceedings, 2004, 79, 946-947.	3.0	1
115	Treatment of localised prostate cancer with radiation therapy: evidence versus opinion. Clinical and Translational Oncology, 2010, 12, 315-317.	2.4	1
116	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. Practical Radiation Oncology, 2020, 10, e378-e387.	2.1	1
117	A method for size estimation for small objects and its application in brachytherapy seed identification. , 2004, , .		0
118	LETTER TO THE EDITOR. Cancer Journal (Sudbury, Mass), 2005, 11, 432.	2.0	0
119	Seed based registration for intraoperative brachytherapy dosimetry: a comparison of methods. , 2006, , .		0
120	In Reply to Drs. Oton and Oton. International Journal of Radiation Oncology Biology Physics, 2008, 71, 962-963.	0.8	0
121	Response to Drs Rogers, Hayes, and Demanes. Brachytherapy, 2014, 13, 523-525.	0.5	O
122	Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? Eur Urol 2017;71:349–50. European Urology, 2017, 71, 351-352.	1.9	0
123	Sternum First, Perhaps Pelvis Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 496.	0.8	O
124	In response to Dover et al Practical Radiation Oncology, 2021, , .	2.1	0
125	PSA screening in men newly diagnosed with colorectal cancer: each according to his group's means?. Oncology, 2013, 27, 1038, 1040.	0.5	0
126	The ABR 2021 Radiation Oncology Remote Examinations: Development, Administration, and Implications for the Future. Journal of the American College of Radiology, 2022, , .	1.8	0